Citation Impact
Citing Papers
Treatment of kidney cancer
2009 StandoutNobel
Occurrence of the potent mutagens 2- nitrobenzanthrone and 3-nitrobenzanthrone in fine airborne particles
2019 Standout
Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations
2007 StandoutNobel
Down-Regulation of Na+/K+ATPase Activity by Human Parvovirus B19 Capsid Protein VP1
2013 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Targeting hypoxia in cancer therapy
2011 Standout
Hepatocyte swelling leads to rapid decrease of the G‐/total actin ratio and increases actin mRNA levels
1992
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018 Standout
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Postprandial Hypoglycemia in Patients after Gastric Bypass Surgery Is Mediated by Glucose-Induced IL-1β
2020
MOLECULAR MECHANISM OF GENOTOXICITY OF THE ENVIRONMENTAL POLLUTANT 3-NITROBENZANTHRONE
2005
The von Hippel–Lindau Tumor Suppressor Gene
2001 StandoutNobel
The Influence of Macromolecular Crowding and Macromolecular Confinement on Biochemical Reactions in Physiological Media
2001 Standout
Keap1-dependent Proteasomal Degradation of Transcription Factor Nrf2 Contributes to the Negative Regulation of Antioxidant Response Element-driven Gene Expression
2003 Standout
Molecular basis of the VHL hereditary cancer syndrome
2002 StandoutNobel
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
2014
The von Hippel‐Lindau Tumor Suppressor Protein: An Update
2007 StandoutNobel
Head and neck cancer
2008 Standout
The changing landscape of atherosclerosis
2021 StandoutNature
The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing
2003 StandoutNobel
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
2010 Standout
Increase of c‐jun mRNA upon hypo‐osmotic cell swelling of rat hepatoma cells
1994
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
2013
SGLT inhibitors in management of diabetes
2013
Sodium–glucose cotransporter-2 inhibition and the potential for renal protection in diabetic nephropathy
2014
Structural reaction pattern of hepatocytes following exposure to hypotonicity
1993
Clinical Pharmacokinetic, Pharmacodynamic, and Drug–Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor
2015
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
2014
Non-alcoholic fatty liver disease
2021 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
2005 Standout
Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
2014
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
2003 StandoutNobel
Type 2 diabetes
2017 Standout
Air pollution and health
2002 Standout
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
2014
Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
2000
Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck
1998
Anisoosmotic Regulation of Hepatic Gene Expression
1996
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck
2007
Genetic Analysis of Pathways Regulated by the von Hippel-Lindau Tumor Suppressor in Caenorhabditis elegans
2004 StandoutNobel
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
2014
Human hemoglobin-derived peptides exhibit antimicrobial activity: a class of host defense peptides
2003
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
2002 StandoutNobel
Regulation of endothelial barrier function during flow-induced conversion to an arterial phenotype
2007 StandoutNobel
Real-time RT-PCR normalisation; strategies and considerations
2005 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Inflammation in obesity, diabetes, and related disorders
2022 Standout
NAD(P)H:Quinone Oxidoreductase 1: Role as a Superoxide Scavenger
2004
Polymorphism of Quinone-metabolizing Enzymes and Susceptibility to Ozone-induced Acute Effects
2001
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
Mechanism of endothelial cell shape change and cytoskeletal remodeling in response to fluid shear stress
1996
Liver cell volume and protein synthesis
1992
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
2013
Chronic Kidney Disease Diagnosis and Management
2019 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
2009 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Activation of persulfate (PS) and peroxymonosulfate (PMS) and application for the degradation of emerging contaminants
2017 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
A NAD(P)H:Quinone Oxidoreductase 1 Polymorphism Is a Risk Factor for Human Colon Cancer
2006
Diabetic Cardiomyopathy
2018 Standout
Osmoregulated taurine transport in H4IIE hepatoma cells and perfused rat liver
1997
β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 Inhibitors
2015
Oxidative DNA damage: mechanisms, mutation, and disease
2003 Standout
Comprehensive Survey of Combinatorial Library Synthesis: 2005
2006
β-Selective C-Arylation of Diisobutylaluminum Hydride Modified 1,6-Anhydroglucose: Synthesis of Canagliflozin without Recourse to Conventional Protecting Groups
2015
pVHL Modification by NEDD8 Is Required for Fibronectin Matrix Assembly and Suppression of Tumor Development
2004 StandoutNobel
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia
2013
The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures
2003 Standout
Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes
2013
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
2007 StandoutNobel
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Functional Significance of Cell Volume Regulatory Mechanisms
1998 Standout
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
2014
Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver
1993
Modulation of phosphoenolpyruvate carboxykinase mRNA levels by the hepatocellular hydration state
1994
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
Dapagliflozin in Patients with Chronic Kidney Disease
2020 Standout
VHL Induces Renal Cell Differentiation and Growth Arrest through Integration of Cell-Cell and Cell-Extracellular Matrix Signaling
2001
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial
2013
Role ofVHLGene Mutation in Human Cancer
2004 StandoutNobel
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Dietary indoles and isothiocyanates that are generated from cruciferous vegetables can both stimulate apoptosis and confer protection against DNA damage in human colon cell lines.
2001
myo-Inositol is an osmolyte in rat liver macrophages (Kupffer cells) but not in RAW 264.7 mouse macrophages
1997
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
2013
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
2014
Oxidative Stress, Human Genetic Variation, and Disease
2001
Works of Peter Eickelmann being referenced
Increase of β‐actin mRNA upon hypotonic perfusion of perfused rat liver
1991
Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors
2011
Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats
2011
Identification and functional characterization of hemorphins VV‐H‐7 and LVV‐H‐7 as low‐affinity agonists for the orphan bombesin receptor subtype 3
2003
Chemosensitivity of head and neck squamous carcinoma cell lines is not primarily correlated with glutathione level but is modified by glutathione depletion
1996
Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies
1997
Free Radicals in Toxicology:Redox Cycling and NAD(P)H:Quinone Oxidoreductase
1996
Lowered amounts of the tissue-specific transcription factor LFB1 (HNF1) correlate with decreased levels of glutathione S-transferase alpha messenger RNA in human renal cell carcinoma.
1994
Design of Selective Peptidomimetic Agonists for the Human Orphan Receptor BRS-3
2003